Alector Inc.
Clinical trials sponsored by Alector Inc., explained in plain language.
-
Could this injection slow memory loss in early Alzheimer's?
Disease control CompletedThis study tested an experimental drug called AL002 in 356 people with early Alzheimer's disease. The goal was to see if it could slow down memory and thinking problems compared to a placebo. Participants received either the drug or a dummy treatment for 96 weeks, and researchers…
Phase: PHASE2 • Sponsor: Alector Inc. • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
New drug shows promise for inherited dementia
Disease control CompletedThis study tested an experimental drug called AL001 in 33 people with frontotemporal dementia caused by specific gene mutations (GRN or C9orf72). The main goals were to check safety and how the drug moves through the body. Researchers also measured changes in certain proteins in …
Phase: PHASE2 • Sponsor: Alector Inc. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC